Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose LY3461767 in chronic heart failure with reduced ejection fraction
jRCT2031210456Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing LY3461767 with Placebo (2 arms). Primary endpoint: Number of participants with one or more serious adverse events related to study drug. Started Dec 2021; status: completed.
02
Drugs
LY3461767
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2031210456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210456.